文献速递皮肤肿瘤

新辅助伊匹木单抗联合纳武利尤单抗治疗原发或移行转移黑色素瘤

Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
PubMed 文献 · Br J Dermatol · 2019-12-26

本文报道4例伴有移行转移或晚期原发肿瘤的黑色素瘤患者,按OpACIN-neo试验B方案接受新辅助伊匹木单抗联合纳武利尤单抗治疗。所有患者均达到影像学疾病控制和病理缓解,截至报告时无一例复发。背景中提及既往新辅助双免疫联合治疗在III期黑色素瘤中病理缓解率77%,3/4级不良事件发生率20%,但既往试验排除了移行转移患者。

要点

  • 新辅助伊匹木单抗联合纳武利尤单抗可使移行转移或晚期原发黑色素瘤患者达到影像学疾病控制和病理缓解。
  • 本组4例患者截至报告时均未复发。
  • 既往新辅助双免疫试验排除了移行转移患者,本报告补充了该人群的初步数据。

核心结论

  • 在4例伴有移行转移或晚期原发肿瘤的黑色素瘤患者中,按OpACIN-neo试验B方案行新辅助伊匹木单抗联合纳武利尤单抗治疗,所有患者均达到影像学疾病控制和病理缓解,截至报告时无一例复发。

研究设计与样本

  • 本文为病例报告,纳入4例伴有移行转移或晚期原发肿瘤的黑色素瘤患者。
  • 治疗方案参照OpACIN-neo试验B方案:伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg,共两周期。

主要发现

  • 4例患者均达到影像学疾病控制。
  • 4例患者均达到病理缓解。
  • 截至报告时,无一例患者复发。

关键数值与推荐

  • 既往新辅助伊匹木单抗(1 mg/kg)联合纳武利尤单抗(3 mg/kg)两周期治疗III期黑色素瘤的研究中,77%的患者出现病理缓解。
  • 同一研究中,20%的患者发生3级或4级不良事件。

临床怎么用

  • 对于伴有移行转移或晚期原发肿瘤的黑色素瘤患者,可考虑按OpACIN-neo试验B方案行新辅助伊匹木单抗联合纳武利尤单抗治疗。
  • 治疗过程中需监测影像学应答和病理缓解,并关注不良事件。

局限性

  • 本文仅为4例患者的病例报告,样本量小,证据级别有限。
  • 既往新辅助双免疫联合治疗试验排除了移行转移患者,本报告仅提供该人群的初步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of new therapeutic agents has revolutionized the treatment of metastatic melanoma. The approval of adjuvant anti-programmed death-1 monotherapy with nivolumab or pembrolizumab, and dabrafenib plus trametinib has recently set a new landmark in the treatment of stage III melanoma. Now, clinical trials have shown that immune checkpoint blockade can be performed in a neoadjuvant setting, an approach established as a standard therapeutic approach for other tumour entities such as breast cancer. Recent studies suggest that a pathological response achieved by neoadjuvant immunotherapy is associated with long-term tumour control and that short neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy. Most recently, neoadjuvant ipilimumab plus nivolumab in stage III melanoma was reported. With two courses of dose-optimized ipilimumab (1 mg kg-1 ) combined with nivolumab (3 mg kg-1 ), pathological responses were observed in 77% of patients, while only 20% of patients experienced grade 3 or 4 adverse events. However, the neoadjuvant trials employing combined immune checkpoint blockade conducted so far have excluded patients with in transit metastases, a common finding in stage III melanoma. Here we report four patients with in transit metastases or an advanced primary tumour who have been treated with neoadjuvant ipilimumab plus nivolumab according to the OpACIN-neo trial scheme (arm B). All patients achieved radiological disease control and a pathological response. None of the patients has relapsed so far. Linked Comment: Blankenstein and van Akkooi. Br J Dermatol 2020; 183:421-422.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Weber J, Glutsch V, Geissinger E, et al. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease. Br J Dermatol. 2019. PMID: 31773720. doi:10.1111/bjd.18739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。